Category: Management

• Interest in genetic testing and risk-reducing behavioral changes: results from a community health assessment in New York City.
• Lima SM, Nazareth M, Schmitt KM, Reyes A, Fleck E, Schwartz GK, Terry MB, Hillyer GC.
• J Community Genet. 2022 Oct 13. doi: 10.1007/s12687-022-00610-2. Epub ahead of print.

• PMID: 36227532
• PubMed abstract
• Source abstract

• Genetic Testing Challenges in Oncology: Missed Variant Update Delays Li-Fraumeni Diagnosis.
• Ray T.
• Precision Oncology News. 2022 Oct 12.

• Case report
• Free Full Text

Related:

Special article:

Is there a duty to reinterpret genetic data? The ethical dimensions.

• PMID: 31616070
• PubMed abstract
• Free Full Text

• An updated counseling framework for moderate-penetrance colorectal cancer susceptibility genes.
• Breen KE, Katona BW, Catchings A, Ranganathan M, Marcell V, Latham A, Yurgelun MB, Stadler ZK.
• Genet Med. 2022 Oct 12:S1098-3600(22)00918-2. doi: 10.1016/j.gim.2022.08.027. Epub ahead of print.

• PMID: 36222830
• PubMed abstract
• Source abstract

• A novel germline mutation of TP53 with breast cancer diagnosed as Li-Fraumeni syndrome.
• Kai M, Kubo M, Shikada S, Hayashi S, Morisaki T, Yamada M, Takao Y, Shimazaki A, Harada Y, Kaneshiro K, Mizuuchi Y, Shindo K, Nakamura M.
• Surg Case Rep. 2022 Oct 11;8(1):197. doi: 10.1186/s40792-022-01546-y.

• PMID: 36219266
• PubMed abstract

• Case report
• Free Full Text

• Study: Teens and young adults respond well to learning about familial cancer risk
• [No author given]
• FORCE. XRAY. 2022 Oct 11.

• Research news
• Free Full Text

Related:

Original research:

Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.

• PMID: 35859209
• PubMed abstract
• Source abstract

Commentary:

Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.

• PMID: 35859132
• PubMed abstract
• Source abstract

• Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
• Bahar-Shany K, Barnabas GD, Deutsch L, Deutsch N, Glick-Saar E, Dominissini D, Sapoznik S, Helpman L, Perri T, Blecher A, Katz G, Yagel I, Rosenblatt O, Shai D, Brandt B, Meyer R, Mohr-Sasson A, Volodarsky-Perel A, Zilberman I, Armon S, Jakobson-Setton A, Eitan R, Kadan Y, Beiner M, Josephy D, Brodsky M, Friedman E, Anafi L, Molchanov Y, Korach J, Geiger T, Levanon K.
• Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318. Epub ahead of print.

• PMID: 36214786
• PubMed abstract
• Source abstract

Related:

Identifier: NCT03150121: Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage (BEDOCA). (ClinicalTrials.gov . Accessed 2022 Oct 10.)

• Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
• Powell CB, Laurent C, Garcia C, Hoodfar E, Karlea A, Kobelka C, Lee J, Roh J, Kushi LH.
• Gynecol Oncol. 2022 Oct 8:S0090-8258(22)01857-1. doi: 10.1016/j.ygyno.2022.10.001. Epub ahead of print.

• Source abstract

• Ovarian cancer risk management in BRCA-mutation carriers: A comparison of six international and national guidelines.
• Matan LS, Perri T, Kogan L, Brandt B, Meyer R, Levin G.
• Eur J Obstet Gynecol Reprod Biol. 2022 Sep 29;278:166-171. doi: 10.1016/j.ejogrb.2022.09.035. Epub ahead of print.

• PMID: 36208522
• PubMed abstract
• Source abstract

• Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
• Harper JB, Greenberg SE, Hunt TC, Cooney KA, O'Neil BB.
• Prostate. 2022 Oct 7. doi: 10.1002/pros.24447. Epub ahead of print.

• PMID: 36207779
• PubMed abstract
• Source abstract